H. pylori causes a variety of intragastric and extragastric diseases, including gastritis, gastric ulcers, gastric cancer, duodenal ulcers, lymphoid tissue lymphoma, and anemia. Current treatment of H. pylori primarily relies on antibiotics. The resistance of H. pylori to different antibiotics reduces the effectiveness of antibiotic therapy. There is an urgent need to develop several new H. pylori drugs to treat H. pylori. Ace Infectious helps the entire pre-clinical process of H. pylori drug development and provides eight services to support H. pylori drug development. Below is a brief description of our H. pylori drug development services.
We provide target discovery and validation services for the development of H. pylori drugs. We use the genetic information and various mechanisms (such as survival and colonization mechanisms) of H. pylori to discover new drug targets and construct ideal in vivo and in vitro models to validate the targets.
Target-based drug discovery is considered to be an efficient method for drug discovery. Ace Infectious offers drug discovery services for ten types of potential H. pylori drug targets. These drug target types cover a wide range of aspects of H. pylori survival, colonization, pathogenesis, and antibiotic resistance.
To meet the need for the discovery of different types of drugs for H. pylori, we offer to develop natural product-based drugs, small molecule drugs, and therapeutic peptides and proteins. We offer a suite of services for the development of small molecule drugs from hit discovery to lead optimization and we offer discovery and optimization services for therapeutic peptides and proteins. What's more, we provide drug delivery system development to improve drug efficacy.
To better support H. pylori drug development, we provide drug analysis services and drug synthesis services to save development time through effective bridging.
Our services meet almost all the needs of pre-clinical drug development for H. pylori. This broad range of services gives us the ability to provide our clients with a one-stop shop for pre-clinical drug development for H. pylori.
Professional H. pylori developers
Our H. pylori professionals can provide comprehensive basic support for the development of H. pylori drugs through their in-depth research on various mechanisms and characteristics of H. pylori. They play an important role in H. pylori drug target discovery, target validation, and target-based drug development.
Senior chemist and computer specialist
The successful development of small molecule drugs for H. pylori is enhanced by our experienced chemists and computer experts who work in collaboration with H. pylori experts.
We have advanced testing equipment. We can achieve precise analysis of targets, efficient high-throughput screening of drugs, and accurate analysis of drugs.
Intelligent data recording and barrier-free communication
Our experimental data are uploaded to the cloud space in real-time for all project stakeholders to view and analyze. We have also set up a message system under the project to facilitate collaboration and negotiation on various drug development-related issues.
Cooperate with us
Ace Infectious is committed to being a one-stop shop for H. pylori drug pre-clinical research and we provide comprehensive H. pylori drug preclinical research services, including target discovery, target validation, hit discovery, hit to lead, lead optimization, small-scale synthesis, drug analysis, and drug delivery system development. We are a professional H. pylori drug preclinical development service provider. Work with us to achieve your H. pylori drug development efficiently, rapidly, and economically.
- Liu, C.; et al. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therapeutic Advances in Gastroenterology. 2021, 14: 1756284821989177.
- Hu, Y.; et al. Recent progress in Helicobacter pylori treatment. Chinese Medical Journal. 2020, 133(03): 335-43.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.